Acadia is now up 49% in the last 12 months compared to -37% for Neuren. Even before the large jump, Acadia was outperforming Neuren despite the legal uncertainty with their current larger revenue marker. When that factor has been removed it seems obvious the market has been harsher to Neuren based on Daybue because NNZ-2591 has continued to best expectations and the FDA endpoint issue has been resolved.
NEU Price at posting:
$13.19 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)